Listen on the go
  • Listen on the Go
  • Listen on the Go
  • Listen on the Go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Download Practice Aid
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. John Chen

    Mayo Clinic, Rochester, MN, USA

    John Chen is a consultant and professor of ophthalmology and neurology, and neuro-ophthalmology fellowship director at the Mayo Clinic in Rochester, MN, USA.read more

    Prof. Chen’s main interests are ophthalmic imaging, idiopathic intracranial hypertension and optic neuritis, especially NMOSD and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

    Prof. Chen is a board member for the North American Neuro-Ophthalmology Society and is on multiple committees for the American Academy of Ophthalmology (AAO). He co-chairs the Upper Midwest Neuro-Ophthalmology Group, is a member of the American Ophthalmological Society and American Eye Study Club, and he previously served as the president for the Minnesota Academy of Ophthalmology.

    He has over 200 peer-reviewed publications and has delivered over 200 oral presentations, including multiple named lectureships and visiting professorships.

    Prof. John Chen Discloses: Consultancy fees from Horizon and UCB.
    Prof. Friedemann Paul

    Charité - Universitätsmedizin Berlin, Germany

    Friedemann Paul is a professor at Charité – Universitätsmedizin Berlin, where he directs the Neuroimmunology Group and Multiple Sclerosis Research Center. He also serves as the head of the Experimental and Clinical Research Center (ECRC).read more

    Prof. Paul is a renowned neurologist specializing in neuroimmunology. With a profound dedication to advancing medical research, Prof. Paul has made significant contributions to the understanding and treatment of multiple sclerosis and other neuroimmunological disorders. His extensive publication record, coupled with numerous awards and accolades, underscores his commitment to improving patient care and fostering innovation in neurology.

    Prof. Friedemann Paul Discloses: Advisory board or panel fees from Alexion Pharma, Amgen, Biogen, Chugai Pharma, Förderpreis, Hexal, Horizon, Merck, Novartis, Novartis Pharma, Ridgeline Discovery, Roche, Sanofi, Teva GmbH and UCB. Consultancy fees from BioNTech, Bristol Myers Squibb, Hexal AG, Hoffmann-La Roche, MIAC AG, Roche Pharma and UCB Biopharma. Grants/research Support from Alexion, Amgen, Hexal (relationship terminated), Horizon, Novartis, Roche, Sanofi (relationship terminated) and UCB.
    touchOPHTHALMOLOGY touchOPHTHALMOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Neuro-ophthalmology

    An Introduction to Neuro-ophthalmology

    Neuro-ophthalmology is a challenging area that incorporates many conditions that affect the neurological control of the visual system, such as strabismus and optic neuritis. Management often requires a multidisciplinary approach involving ophthalmology and neurology specialists.

    Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Neuro-ophthalmology Content

    Neuro-ophthalmology
    Watch Time: 39 mins
    touchIN CONVERSATION
    Early diagnosis and treatment of NMOSD: Practical insights
    CE/CME ACCREDITED Prof. John Chen, Prof. Friedemann Paul Translations available:

    A neurologist and a neuro-ophthalmologist discuss best practices for early diagnosis and treatment of NMOSD

    Learning objectives
    Learning Objectives
    • Identify the initial symptoms of NMOSD and its clinical characteristics at presentation
    • Apply appropriate processes to ensure accurate and rapid diagnosis of NMOSD
    • Choose appropriate management strategies based on patient symptoms and biomarker tests
    touchEXPERT BRIEFING
    Why is an early diagnosis of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) important?
    For HCPs in: Global (excluding USA)
    View Time: 24 mins Sponsored content

    Watch this multidisciplinary discussion on the importance of overcoming challenges to establish an early and accurate gMG and NMOSD diagnosis

     

    M/INT/UNB-g/0192
    Date of Preparation: June 2024
    Neuro-ophthalmology
    Pharmacologic Mydriasis and Cycloplegia: A Review of Novel Delivery Devices
    Jalin A Jordan, Julius T Oatts

    touchREVIEWS in Ophthalmology. 2023;17(2):19-22 DOI: https://doi.org/10.17925/USOR.2023.17.2.2

    Mydriasis physiology Mydriasis refers to physiologic or pharmacologic pupillary dilation. Physiologic pupillary dilation occurs naturally as a response to low light and viewing objects in the distance. This process is mediated by both the iris sphincter and the iris dilator muscles, the latter of which contracts in response to sympathetic stimulation and relaxes in response to […]

    Neuro-ophthalmology
    Watch Time: 36 mins
    touchPANEL DISCUSSION
    The complement system in NMOSD and MG: A target for therapeutic benefit?
    CE/CME ACCREDITED Prof. Said Beydoun, Dr Pushpa Narayanaswami, Prof. Heinz Wiendl

    Watch specialists in neurological disorders share their insights on the role of complement and complement therapeutics in patients with neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG).

    Learning objectives
    Learning Objectives
    • Describe the role of complement in the pathophysiology of NMOSD and MG
    • Evaluate markers of complement activation as diagnostic and prognostic biomarkers in NMOSD and MG
    • Discuss recently approved and experimental inhibitors of the complement system for the treatment of NMOSD and MG
    Neuro-ophthalmology
    Watch Time: 49 mins
    touchSATELLITE SYMPOSIUM
    Latest developments in neuromyelitis optica spectrum disorder: Diagnostics, treatments and patient-centred care
    CE/CME ACCREDITED Dr Dalia Rotstein, Dr Eoin Flanagan, Dr Jeffrey Bennett

    Three experts examine evidence-based approaches for early and accurate diagnosis, appropriate treatment selection and patient-centred care to mitigate the clinical burden of neuromyelitis optica spectrum disorder.

    Learning objectives
    Learning Objectives
    • Recall strategies that facilitate an early and accurate diagnosis of NMOSD
    • Describe how evidence from clinical trials investigating current and emerging treatments for NMOSD informs clinical decision making
    • Select individualized management plans for patients with NMOSD to reduce the patient-reported burden of symptoms
    Neuro-ophthalmology
    Current and Emerging Therapies for Leber Hereditary Optic Neuropathy
    Pamela Davila-Siliezar, Noor Laylani, Konstantinos AA Douglas

    touchREVIEWS in Ophthalmology. 2023;17(1):21–24 DOI: https://doi.org/10.17925/USOR.2023.17.1.21

    Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited optic nerve disease characterized by bilateral (sequential or simultaneous), subacute, painless central vision loss.1 LHON was first described in 1871 by the German ophthalmologist Theodor Leber.2 However, it was not until 1988 that the mitochondrial mutation was discovered by Wallace et al.3 LHON is the most common hereditary mitochondrial optic neuropathy. Several primary mitochondrial […]

    Neuro-ophthalmology
    Developed by Touch
    Mark Moster: RESCUE, REVERSE and RESTORE clinical trials: Investigating gene therapy for Leber’s hereditary optic neuropathy
    Watch Time: 5 mins

    Leber’s hereditary optic neuropathy (LHON) is characterized by bilateral, painless subacute loss of central vision during young adult life. We were delighted to speak with Prof. Mark Moster (Wills Eye Hospital, Philadelphia, PA, USA) to discuss the findings in the RESCUE, REVERSE and RESTORE clinical trials.  Questions: Could you give us a brief overview of […]

    Neuro-ophthalmology
    Watch Time: 64 mins
    touchSATELLITE SYMPOSIUM
    Considering the complete picture in neuromyelitis optica spectrum disorder: Optimizing diagnosis and management to improve patient outcomes
    CE/CME ACCREDITED Prof. Sean Pittock, Prof. Dean Wingerchuk, Dr Amy Kunchok

    Watch three leading experts discuss diagnosis, treatment and care provision for patients with neuromyelitis optica spectrum disorder (NMOSD), with updates on the latest data for immunotherapy treatment options and guidance on how to support the holistic management of patients through multidisciplinary teams.

    Learning objectives
    Learning Objectives
    • Describe the clinical manifestations of neuromyelitis optica spectrum disorder (NMOSD), the typical MRI findings and differential diagnoses
    • Analyse the treatment options for the prevention of NMOSD attacks and their selection criteria
    • Determine strategies for the holistic management of the broad range of symptoms experienced by patients with NMOSD
    Neuro-ophthalmology
    Ben Thompson, ARVO 2021: Latest Studies on Interventions for Visual Cortex Neuroplasticity

    It was a pleasure to catch up with Ben Thompson (University of Waterloo, Waterloo, ON, Canada), to discuss the latest clinical data on interventions for the enhancement of visual cortex neuroplasticity. Questions What interventions enhancing visual cortex neuroplasticity are currently being investigated in humans with amblyopia? (00:15) Could you give us a brief overview of […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchOPHTHALMOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup